Yemen

Support for Vaccine: Inactivated Polio Virus
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Yemen


3. **Date of Decision Letter:** July 11, 2019

4. **Date of the Partnership Framework Agreement:** Not applicable

5. **Programme title:** New Vaccine Support (NVS), Inactivated Polio Virus, Routine

6. **Vaccine type:** Inactivated Polio Virus

7. **Requested product presentation and formulation of vaccine:**
   - Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration:** 2014-2019

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5,321,103</td>
<td>1,983,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,304,103</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant**

    **Approval**

    | Year | Grant Number | Amount (US$) |
    |------|--------------|--------------|
    | 2014 | 14-YEM-08h-Y | 614,000      |

    **Disbursement**

    | Disbursement date | Amount (US$) |
    |-------------------|--------------|
    | 25 July, 2014     | 614,000      |

11. **Product switch grant**

    Not applicable

12. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds</th>
<th>2014-2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td></td>
<td>664,100</td>
<td>-</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>5,321,103</td>
<td>1,983,000</td>
<td>-</td>
</tr>
</tbody>
</table>

[^1]: This is the entire duration of the Programme.
[^2]: This is the total amount endorsed by Gavi for the entire duration of the Programme.
[^3]: This is the total amount approved by Gavi.
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:
   Not applicable
   Gavi’s usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for catch-up campaigns:
   Not applicable

17. Additional Reporting Requirements:

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>* vaccine stock levels including buffer stock, by end of March;</td>
<td>March 31, 2020</td>
</tr>
<tr>
<td>* number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</td>
<td>May 15, 2020</td>
</tr>
<tr>
<td>* Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td></td>
</tr>
</tbody>
</table>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

Periodicity and dates to be agreed with Gavi Secretariat

18. Financial clarifications: Country shall provide the following clarifications to Gavi*:
   Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:
   Not applicable
Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Yemen envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Yemen.

On behalf of Gavi

[Signature]

Pascal Bijleveld
Managing Director, Country Programmes  a.i.